This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. | |
|---|---|
| Case name | Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. |
| Court | United States Supreme Court |
| Decided | 2010 |
| Citations | 598 F.3d 1336 (Fed. Cir.), cert. granted, 2010 U.S. LEXIS 1251; 559 U.S. 1200 (2010) |
| Judges | Stevens (ret.), Scalia, Kennedy, Thomas, Ginsburg, Breyer, Alito, Sotomayor, Kagan |
| Prior | Judgment for defendant on grounds of invalidity, United States Court of Appeals for the Federal Circuit |
| Subsequent | Remanded to Federal Circuit |
Ariad Pharmaceuticals, Inc. v. Eli Lilly and Co. was a major patent-law dispute concerning the written description and enablement requirements for biotechnology patents and the scope of patent-eligibility doctrine in United States jurisprudence. The litigation involved biotechnology firms, academic institutions, and pharmaceutical markets, implicating statutory interpretation of Title 35 of the United States Code and doctrines developed by the United States Court of Appeals for the Federal Circuit and the Supreme Court. The case influenced patent prosecution, biotechnology investment, and litigation strategy across the United States and globally.
Ariad Pharmaceuticals, a biotechnology company with ties to research at Massachusetts Institute of Technology and Harvard University, held patents claiming methods of reducing activity of nuclear factor-kappa B by inhibiting its localization or activation. Eli Lilly and Company, a multinational pharmaceutical corporation headquartered in Indianapolis, Indiana, developed drugs and research programs involving nuclear factor-kappa B pathways and challenged Ariad's patents in infringement and validity litigation. The dispute brought together actors from the biotechnology industry, including research institutions such as Broad Institute and firms like Amgen, and raised issues under statutes and precedents including 35 U.S.C. § 112, Diamond v. Diehr, Mayo Collaborative Services v. Prometheus Laboratories, Inc., and standards from the United States Court of Appeals for the Federal Circuit.
The case began in the United States District Court for the District of Massachusetts, where Ariad sued Lilly for patent infringement. The district proceedings featured expert testimony from scientists affiliated with Massachusetts General Hospital, Dana-Farber Cancer Institute, and university laboratories, while Lilly marshaled defenses citing prior art from journals like Nature and Science and patents held by actors including Genentech and Genzyme. The district court construed claim language, applied the written description and enablement requirements of 35 U.S.C. § 112, and relied on Federal Circuit precedent such as University of Rochester v. G.D. Searle & Co. and In re Ruschig. The court ultimately found the asserted claims invalid for failure to satisfy the statutory requirements and entered judgment for Lilly.
Ariad appealed to the United States Court of Appeals for the Federal Circuit, where an en banc panel considered the scope of the written description requirement and whether § 112 contains separate written description and enablement mandates. The Federal Circuit analyzed earlier decisions like Festo Corp. v. Shoketsu Kinzoku Kogyo Kabushiki Co. and In re Alton and examined patent prosecution histories tied to corporate actors such as Pfizer and Bristol-Myers Squibb. The court affirmed invalidity, interpreting § 112 to require a distinct written description showing the inventor possessed the claimed invention at the time of filing, particularly in the context of biotechnology claims that encompassed broad functional language affecting molecular pathways and signaling proteins.
The Supreme Court granted certiorari, attracting amicus briefs from stakeholders including Biotechnology Industry Organization, American Intellectual Property Law Association, major universities like Stanford University and Yale University, and companies such as Microsoft and Google. The Court evaluated statutory text of United States Code provisions, precedent from decisions like Markman v. Westview Instruments, Inc. and KSR International Co. v. Teleflex Inc., and constitutional considerations tied to the Patent Clause and innovation policy debated in forums like Congress and the United States Patent and Trademark Office. The Supreme Court reversed in part, clarifying the relationship between written description and enablement while remanding to the Federal Circuit for further proceedings.
Central legal issues included whether § 112 contains separate written description and enablement requirements, the appropriate standard for written description in biotechnology claims, and how claim scope relates to disclosure sufficiency. The Supreme Court held that § 112 does encompass a written description requirement distinct from enablement, but it cautioned against rigid rules that would upset settled patent practice from decisions like Diamond v. Chakrabarty. The opinion addressed interplay with doctrines from Myriad Genetics, Inc. v. Association for Molecular Pathology and articulated that functional claiming in biotechnology must be supported by adequate disclosure of concrete embodiments, references to persons such as inventors tied to academic labs, and prior art contexts.
The decision reshaped patent drafting and prosecution strategies across the biotechnology sector, affecting companies like Genentech, Regeneron Pharmaceuticals, and Biogen. Patent applicants increased reliance on detailed molecular sequences, experimental data from institutions like Cold Spring Harbor Laboratory, and narrower claim language to satisfy the written description requirement. The ruling influenced USPTO examination practices, Federal Circuit jurisprudence, and litigation tactics in district courts, prompting debates in policy venues including hearings in United States Congress and commentary from think tanks like Brookings Institution and The Heritage Foundation.
Subsequent litigation invoked the Ariad framework in cases involving patents asserted by entities such as Myriad Genetics, Illumina, and university technology transfer offices at Columbia University and Johns Hopkins University. The decision affected licensing negotiations with pharmaceutical companies like Johnson & Johnson, shaped venture capital investment by firms such as Sequoia Capital and Kleiner Perkins, and informed policy discussions at the World Intellectual Property Organization and the Organisation for Economic Co-operation and Development. The ruling remains a touchstone in debates over patent scope, innovation incentives, and the role of detailed disclosure in fostering research on complex biological systems like signal transduction and inflammatory pathways.